Cytek Biosciences, Inc. (CTKB) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Cytek Biosciences, Inc. (CTKB) stock forecast summary
Our AI ranks Cytek Biosciences, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Cytek Biosciences, Inc. is a small-cap company with a market capitalization of $695M. It ranks number 11 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for CTKB is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CTKB included.
Follow CTKB freeCTKB price chart and AI forecast
How CTKB ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Cytek Biosciences, Inc. (CTKB) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | CTKB | Rank |
|---|---|---|
| Market Cap | $695M | 11/25 |
| P/B Ratio | 2.16x | 14/23 |
| EPS | $-0.63 | – |
| Book Value/Share | $2.48 | – |
| Revenue/Share | $1.59 | – |
| FCF/Share | $-0.09 | – |
Profitability & Margins
| Metric | CTKB | Rank |
|---|---|---|
| ROE | -25.0% | 13/21 |
| ROA | -18.0% | 14/22 |
| ROIC | -12.3% | 11/21 |
| Gross Margin | 53.1% | 7/19 |
| Operating Margin | -21.6% | 12/21 |
| Net Margin | -39.0% | 12/20 |
| EBT Margin | -20.2% | 13/22 |
| Tax Rate | -95.4% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | CTKB | Rank |
|---|---|---|
| Current Ratio | 4.48x | 10/25 |
| Quick Ratio | 3.86x | 8/24 |
| D/E Ratio | 0.39x | 15/24 |
| Financial Leverage | 1.39x | 15/24 |
| Interest Coverage | -24.3x | 12/21 |
| Working Capital | $294M | 10/25 |
Cash Flow
| Metric | CTKB | Rank |
|---|---|---|
| Operating Cash Flow | -$6M | 16/24 |
| Free Cash Flow | -$12M | 14/20 |
| Capital Spending | -$6M | 13/20 |
| OCF Growth YoY | -139.7% | 12/12 |
| FCF Growth YoY | -211.1% | 11/11 |
| FCF/Sales | -5.8% | 12/19 |
| CapEx/Sales | 2.9% | 8/19 |
Operational Efficiency
| Metric | CTKB | Rank |
|---|---|---|
| Asset Turnover | 0.46x | 13/21 |
| Receivables Turnover | 4.2x | 17/19 |
| Inventory Turnover | 1.9x | 11/19 |
| Fixed Assets Turnover | 9.9x | 4/21 |
| Days Sales Outstanding | 88 days | 3/19 |
| Days Inventory | 197 days | 9/19 |
| Payables Period | 0 days | 18/18 |
| Cash Conversion Cycle | 285 days | 1/17 |
Income Statement
| Metric | CTKB | Rank |
|---|---|---|
| Total Revenue | $206M | 10/21 |
| Operating Income | -$44M | 14/21 |
| Net Income | -$80M | 17/22 |
| R&D Expense | $37M | 13/21 |
| SG&A Expense | $158M | 10/20 |
| Cost of Goods Sold | $97M | 10/19 |
Dividend & Shareholder Information
| Metric | CTKB | Rank |
|---|---|---|
| Shares Outstanding | 130M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $378M | 84.6% of assets |
| Cash & Short-term Investments | $74M | 16.5% of assets |
| Accounts Receivable | $50M | 11.1% of assets |
| Inventory | $52M | 11.7% of assets |
| Total Liabilities | $125M | 28.0% of assets |
| Short-term Debt | $84M | 18.9% of assets |
CTKB quarterly financials and insider trading
Cytek Biosciences, Inc. (CTKB) industry peers
Companies classified under the same SEC industry code as Cytek Biosciences, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CTKB Cytek Biosciences, Inc. | ▲ | $695M |
| A Agilent Technologies, Inc. | ▼ | $48.40B |
| WAT Waters Corp /De/ | ▲ | $42.45B |
| ILMN Illumina, Inc. | ▶ | $40.95B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.02B |
| RVTY Revvity, Inc. | ▼ | $17.30B |
| AVTR Avantor, Inc. | ▶ | $10.62B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.73B |
| TXG 10x Genomics, Inc. | ▲ | $9.35B |
| BRKR Bruker Corp | ▲ | $8.56B |
| ALMR Alamar Biosciences, Inc. | ▶ | $1.63B |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $637M |
| MASS 908 Devices Inc. | ▲ | $500M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $275M |
| EYPT Eyepoint, Inc. | ▲ | $265M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $261M |
| QTRX Quanterix Corp | ▲ | $149M |
| SEER Seer, Inc. | ▶ | $119M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $44M |
| PRPO Precipio, Inc. | ▲ | $40M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| ASTC Astrotech Corp | ▶ | $11M |
| SCND Scientific Industries Inc | ▲ | $8M |
Where CTKB sits on the market map
Cytek Biosciences, Inc. (CTKB) stock news
Loading...
Cytek Biosciences, Inc. (CTKB) stock forecast FAQ
What is the Cytek Biosciences, Inc. (CTKB) stock forecast?
Our AI ranks Cytek Biosciences, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Cytek Biosciences, Inc. stock predictions?
A per-ticker accuracy statistic for CTKB is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Cytek Biosciences, Inc. forecasts updated?
Cytek Biosciences, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Cytek Biosciences, Inc.'s industry peers?
25 issuers in our coverage, CTKB included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.